publication date: May. 29, 2020Conversation with The Cancer LetterRamon E. Parsons, MD, PhDDirector, The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai; Ward-Coleman Chair in Cancer Research;Director, Mount Sinai Cancer, Mount Sinai Health System;Chair, Department of Oncological Sciences, Icahn School of Medicine at Mount SinaiThis story is part of The Cancer Letter’s…
The phase I/II LINKER-MM1 trial of linvoseltamab in R/R MM produced positive pivotal data in patients with relapsed/refractory multiple myeloma. To access this subscriber-only content…
An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer…
With NCI funding expected to remain flat through fiscal year 2025, health professionals and leaders in oncology should use this time to amp up institutional…
Nancy Hanley Eriksson and Kevin Conroy received John S. McCain Leadership Awards from Translational Genomics Research Institute (TGen), part of City of Hope, at the…
A renowned surgeon and international authority on breast cancer, American College of Surgeons Past-President Edward (Ted) M. Copeland III, died on March 31 at the…
The FY24 Defense Appropriations Act provides funding for the LCRP to support innovative, high-impact lung cancer research. The managing agent for the anticipated funding opportunities…
To address inequities in cancer health, NCI is collaborating with a diverse team of experts and cancer center directors—named the Cancer Equity Leaders (CEL)—to learn…
Matt Kalaycio was named chair of the board of directors at the National Comprehensive Cancer Network. Christopher H. Lieu was elected as vice chair, succeeding…
Sporting a leprechaun’s hat and a giant green bowtie, Matthew Huesser, DBA, conference chairperson and vice president for cancer research administration at the Sidney Kimmel…
The European Commission expanded the indication of Reblozyl (luspatercept) to include the first-line treatment of adult patients with transfusion-dependent anemia due to very low, low,…
